Caribou Biosciences (CRBU) Accumulated Depreciation & Amortization (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Accumulated Depreciation & Amortization data on file, last reported at $649000.0 in Q1 2026.

• Quarterly Accumulated Depreciation & Amortization fell 44.29% year-over-year to $649000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $649000.0 (down 44.29% YoY) and the FY2025 annual result came in at $3.6 million, down 7.18% from the prior year.
• Accumulated Depreciation & Amortization declined to $649000.0 in Q1 2026 per CRBU's latest filing, from $3.6 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $3.9 million in Q4 2024 and bottomed at $308000.0 in Q1 2022.
• The 5-year median for Accumulated Depreciation & Amortization is $1.6 million (2024), against an average of $1.9 million.
• The widest annual swing landed in 2022, when Accumulated Depreciation & Amortization sank 81.21%; it then surged 149.55% in 2023.
• Tracing CRBU's Accumulated Depreciation & Amortization over 5 years: stood at $1.6 million in 2022, then soared by 117.32% to $3.5 million in 2023, then increased by 11.4% to $3.9 million in 2024, then slipped by 7.18% to $3.6 million in 2025, then sank by 82.19% to $649000.0 in 2026.
• Per Business Quant, the three latest CRBU Accumulated Depreciation & Amortization figures stand at $649000.0 (Q1 2026), $3.6 million (Q4 2025), and $3.0 million (Q3 2025).

Peer Comparison